Ultragenyx Pharmaceutical (NASDAQ:RARE) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Key Points

• Ultragenyx Pharmaceutical reported a quarterly earnings per share of ($1.17), surpassing analysts' expectations by $0.10.
• The company's stock price rose 1.5% to $28.88 following the earnings release, with a trading volume of over 1.4 million shares.
• Analysts maintain a mostly positive outlook, with a Moderate Buy rating and an average price target of $83.08 for the stock.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.10, Zacks reports. The firm had revenue of $166.50 million during the quarter, compared to the consensus estimate of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%. The firm's revenue was up 13.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.52) EPS. Ultragenyx Pharmaceutical updated its FY 2025 guidance to EPS.

Ultragenyx Pharmaceutical Stock Down 1.0%

Shares of RARE traded down $0.29 on Friday, reaching $27.54. The stock had a trading volume of 1,527,932 shares, compared to its average volume of 2,814,751. The firm has a market capitalization of $2.65 billion, a PE ratio of -4.98 and a beta of 0.25. The firm has a 50-day moving average of $33.32 and a 200 day moving average of $36.73. Ultragenyx Pharmaceutical has a twelve month low of $25.81 and a twelve month high of $60.37.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the sale, the director owned 15,344 shares in the company, valued at $573,712.16. This represents a 13.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

An institutional investor recently bought a new position in Ultragenyx Pharmaceutical stock. Creative Planning acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,493 shares of the biopharmaceutical company's stock, valued at approximately $454,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have commented on RARE shares. William Blair assumed coverage on Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price objective for the company. Morgan Stanley cut their target price on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. Wells Fargo & Company cut their target price on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research note on Thursday, July 10th. Guggenheim reissued a "buy" rating and set a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Finally, Canaccord Genuity Group cut their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a research note on Friday. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, Ultragenyx Pharmaceutical has a consensus rating of "Moderate Buy" and an average target price of $81.50.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.